drugset / Trial / NCT05771883
A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.
Timeline
- Start
- 2023-05
- Primary completion
- 2025-05
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM0306 | Protein / enzyme biologic | — | Intravenous |
| Background | Lenalidomide | Other / unclassified | 20 mg | — |
| Background | Lenalidomide | Other / unclassified | 25 mg | — |